MCL1 and Miyoshi myopathy: On this evidence, the lack of toxicity of G-1 on healthy PBMCs could be likely ascribed to their low expression of G-1-oncogenic targets as Sp1, CDK6, and MCL-1, conversely upregulated in malignant plasma cells, whose inhibition instead contributes to G-1 anti-MM activity.